Twentieth century advances in peptide biochemistry and protein sequencing enabled John Brown to purify the first incretin, named GIP, in the 1970s
FIGURE 3 8.4 Health economics and access: important implementation questions, but no PCOS-ART-specific economic evidence yet A structural tension exists between the clinical promise and the cost of GLP-1RAs
In Summary: The tl;dr Grand Finale Ozempic, along with Wegovy, Saxenda, and Mounjaro, has taken the stage as a powerful force in the battle against obesity
Any cloudiness, particulate matter, or discoloration suggests degradation or contamination
Integration capabilities are crucial, especially regarding customization
Taken together, the figure highlights a key mechanistic principle underlying the therapeutic rationale for multi-agonist strategies: while GLP-1R monotherapy achieves meaningful metabolic and hepatic benefits exclusively through indirect, systemic pathways, the addition of GIPR and - most importantly - GCGR co-agonism introduces complementary and increasingly direct hepatic mechanisms, providing the pharmacological basis for the superior efficacy observed with dual and triple agonists in MASLD/MASH
